P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Article2023

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios A Dimopoulos

Article2025

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

María-Victoria Mateos, Vânia Hungria, Meral Beksaç, Paweł Robak, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Gracia Martínez, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, Phoebe Joy Ho, Roman Hájek, Sebastian Grosicki, S. Yousuf Zafar, Al-Ola Abdallah, Jorge Mouro, Zeyad Khalaf, Hena Baig, Ainslee Moore, Chee Paul Lin, Maureen Nichols, Ianire Garrobo-Calleja, Sybil Varghese, Nick Pirooz, Shing Yip Lee, Lydia Eccersley, Elisabet E. Manasanch,

Article2020

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Robert M. Rifkin, Kevin Boyd, Sebastian Grosicki, Kihyun Kım, Francesco Di Raimondo, Meletios A Dimopoulos, Katja Weisel, Bertrand Arnulf, Roman Hájek, Vânia T. M. Hungria, Andrew Spencer, Randy Davis, Antonio Riccio, Chanbin Kim, Jodie Wilkes, Ruth Z. Rutledge, Mala K. Talekar, Brandon E. Kremer, Ira Gupta, María‐Victoria Mateos

Article2025

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).

Meral Beksac, Hang Quach, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda, Ivan Špıčka, Marek Hus, Vera Zherebtsova, Margaret Polinkovsky, Sybil Varghese, Shing Yip Lee, Elisabet E. Manasanch, Paweł Robak, Meletios A Dimopoulos

Article2020

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta,

Discussion(0)

Related publications